Annual Revenue
$2.42 B
+$323.19 M+15.42%
31 December 2023
Summary:
BioMarin Pharmaceutical annual revenue is currently $2.42 billion, with the most recent change of +$323.19 million (+15.42%) on 31 December 2023. During the last 3 years, it has risen by +$558.77 million (+30.03%). BMRN annual revenue is now at all-time high.BMRN Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$745.74 M
+$33.71 M+4.73%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly revenue is currently $745.74 million, with the most recent change of +$33.71 million (+4.73%) on 30 September 2024. Over the past year, it has increased by +$164.41 million (+28.28%). BMRN quarterly revenue is now at all-time high.BMRN Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$2.75 B
+$164.41 M+6.35%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM revenue is currently $2.75 billion, with the most recent change of +$164.41 million (+6.35%) on 30 September 2024. Over the past year, it has increased by +$442.25 million (+19.14%). BMRN TTM revenue is now at all-time high.BMRN TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.4% | +28.3% | +19.1% |
| 3 y3 years | +30.0% | +82.5% | +48.9% |
| 5 y5 years | +62.2% | +61.7% | +71.7% |
BMRN Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +31.0% | at high | +82.5% | at high | +49.1% |
| 5 y | 5 years | at high | +62.2% | at high | +82.5% | at high | +71.7% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high | >+9999.0% |
BioMarin Pharmaceutical Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $745.74 M(+4.7%) | $2.75 B(+6.4%) |
| June 2024 | - | $712.03 M(+9.7%) | $2.59 B(+4.7%) |
| Mar 2024 | - | $648.83 M(+0.4%) | $2.47 B(+2.2%) |
| Dec 2023 | $2.42 B(+15.4%) | $646.21 M(+11.2%) | $2.42 B(+4.7%) |
| Sept 2023 | - | $581.33 M(-2.3%) | $2.31 B(+3.4%) |
| June 2023 | - | $595.27 M(-0.2%) | $2.23 B(+2.8%) |
| Mar 2023 | - | $596.41 M(+11.0%) | $2.17 B(+3.7%) |
| Dec 2022 | $2.10 B(+13.5%) | $537.54 M(+6.4%) | $2.10 B(+4.4%) |
| Sept 2022 | - | $505.34 M(-5.3%) | $2.01 B(+5.1%) |
| June 2022 | - | $533.80 M(+2.8%) | $1.91 B(+1.7%) |
| Mar 2022 | - | $519.36 M(+15.5%) | $1.88 B(+1.8%) |
| Dec 2021 | $1.85 B(-0.8%) | $449.81 M(+10.0%) | $1.85 B(-0.1%) |
| Sept 2021 | - | $408.74 M(-18.5%) | $1.85 B(-3.6%) |
| June 2021 | - | $501.69 M(+3.2%) | $1.92 B(+3.9%) |
| Mar 2021 | - | $486.03 M(+7.5%) | $1.84 B(-0.9%) |
| Dec 2020 | $1.86 B(+9.2%) | $452.12 M(-5.2%) | $1.86 B(-0.1%) |
| Sept 2020 | - | $476.78 M(+11.0%) | $1.86 B(+0.8%) |
| June 2020 | - | $429.49 M(-14.5%) | $1.85 B(+2.3%) |
| Mar 2020 | - | $502.04 M(+10.5%) | $1.81 B(+5.9%) |
| Dec 2019 | $1.70 B(+14.3%) | $454.44 M(-1.4%) | $1.70 B(+6.3%) |
| Sept 2019 | - | $461.10 M(+18.9%) | $1.60 B(+4.5%) |
| June 2019 | - | $387.76 M(-3.2%) | $1.53 B(+1.0%) |
| Mar 2019 | - | $400.75 M(+13.4%) | $1.52 B(+1.8%) |
| Dec 2018 | $1.49 B(+13.5%) | $353.26 M(-9.8%) | $1.49 B(-0.3%) |
| Sept 2018 | - | $391.71 M(+5.1%) | $1.50 B(+4.0%) |
| June 2018 | - | $372.85 M(-0.2%) | $1.44 B(+4.0%) |
| Mar 2018 | - | $373.45 M(+4.2%) | $1.38 B(+5.3%) |
| Dec 2017 | $1.31 B(+17.6%) | $358.31 M(+7.2%) | $1.31 B(+4.6%) |
| Sept 2017 | - | $334.15 M(+5.3%) | $1.26 B(+4.5%) |
| June 2017 | - | $317.45 M(+4.5%) | $1.20 B(+1.5%) |
| Mar 2017 | - | $303.75 M(+1.2%) | $1.18 B(+6.0%) |
| Dec 2016 | $1.12 B(+25.5%) | $300.09 M(+7.2%) | $1.12 B(+6.9%) |
| Sept 2016 | - | $279.90 M(-6.7%) | $1.04 B(+7.3%) |
| June 2016 | - | $300.13 M(+26.8%) | $973.71 M(+5.4%) |
| Mar 2016 | - | $236.74 M(+3.9%) | $923.71 M(+3.8%) |
| Dec 2015 | $889.89 M(+18.8%) | $227.94 M(+9.1%) | $889.89 M(-0.2%) |
| Sept 2015 | - | $208.90 M(-16.5%) | $892.03 M(+3.8%) |
| June 2015 | - | $250.13 M(+23.3%) | $859.67 M(+7.3%) |
| Mar 2015 | - | $202.92 M(-11.8%) | $801.32 M(+6.8%) |
| Dec 2014 | $749.28 M(+36.6%) | $230.07 M(+30.3%) | $749.96 M(+12.5%) |
| Sept 2014 | - | $176.55 M(-7.9%) | $666.76 M(+6.3%) |
| June 2014 | - | $191.79 M(+26.5%) | $627.09 M(+9.6%) |
| Mar 2014 | - | $151.55 M(+3.2%) | $572.11 M(+4.3%) |
| Dec 2013 | $548.49 M(+9.5%) | $146.87 M(+7.3%) | $548.49 M(+2.8%) |
| Sept 2013 | - | $136.87 M(+0.0%) | $533.55 M(+1.7%) |
| June 2013 | - | $136.81 M(+6.9%) | $524.79 M(+2.5%) |
| Mar 2013 | - | $127.93 M(-3.0%) | $512.00 M(+2.3%) |
| Dec 2012 | $500.72 M | $131.94 M(+3.0%) | $500.72 M(+5.1%) |
| Sept 2012 | - | $128.12 M(+3.3%) | $476.63 M(+3.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2012 | - | $124.02 M(+6.3%) | $461.94 M(+3.0%) |
| Mar 2012 | - | $116.65 M(+8.2%) | $448.55 M(+1.6%) |
| Dec 2011 | $441.36 M(+17.3%) | $107.85 M(-4.9%) | $441.36 M(+1.4%) |
| Sept 2011 | - | $113.42 M(+2.5%) | $435.13 M(+3.7%) |
| June 2011 | - | $110.63 M(+1.1%) | $419.45 M(+4.7%) |
| Mar 2011 | - | $109.46 M(+7.7%) | $400.77 M(+6.5%) |
| Dec 2010 | $376.27 M(+15.9%) | $101.61 M(+4.0%) | $376.27 M(+4.0%) |
| Sept 2010 | - | $97.75 M(+6.3%) | $361.74 M(+4.9%) |
| June 2010 | - | $91.95 M(+8.2%) | $344.79 M(+2.7%) |
| Mar 2010 | - | $84.95 M(-2.4%) | $335.63 M(+3.4%) |
| Dec 2009 | $324.66 M(+9.5%) | $87.08 M(+7.8%) | $324.66 M(-3.6%) |
| Sept 2009 | - | $80.81 M(-2.4%) | $336.85 M(+2.5%) |
| June 2009 | - | $82.79 M(+11.9%) | $328.69 M(+6.0%) |
| Mar 2009 | - | $73.98 M(-25.5%) | $310.08 M(+4.6%) |
| Dec 2008 | $296.49 M(+143.9%) | $99.28 M(+36.7%) | $296.49 M(+22.5%) |
| Sept 2008 | - | $72.65 M(+13.2%) | $242.07 M(+24.5%) |
| June 2008 | - | $64.17 M(+6.3%) | $194.43 M(+22.2%) |
| Mar 2008 | - | $60.40 M(+34.7%) | $159.14 M(+30.9%) |
| Dec 2007 | $121.58 M(+44.4%) | $44.85 M(+79.4%) | $121.58 M(+23.1%) |
| Sept 2007 | - | $25.01 M(-13.4%) | $98.75 M(+0.1%) |
| June 2007 | - | $28.88 M(+26.5%) | $98.67 M(+5.8%) |
| Mar 2007 | - | $22.84 M(+3.7%) | $93.23 M(+10.7%) |
| Dec 2006 | $84.21 M(+228.1%) | $22.02 M(-11.7%) | $84.21 M(+17.5%) |
| Sept 2006 | - | $24.93 M(+6.3%) | $71.66 M(+31.9%) |
| June 2006 | - | $23.45 M(+69.8%) | $54.32 M(+57.5%) |
| Mar 2006 | - | $13.81 M(+45.8%) | $34.49 M(+34.4%) |
| Dec 2005 | $25.67 M(+37.7%) | $9.47 M(+25.0%) | $25.67 M(-14.7%) |
| Sept 2005 | - | $7.58 M(+109.0%) | $30.09 M(+32.6%) |
| June 2005 | - | $3.63 M(-27.3%) | $22.69 M(-4.0%) |
| Mar 2005 | - | $4.99 M(-64.1%) | $23.63 M(+26.8%) |
| Dec 2004 | $18.64 M(+54.1%) | $13.90 M(+7577.9%) | $18.64 M(+292.9%) |
| Sept 2004 | - | $181.00 K(-96.0%) | $4.74 M(+4.0%) |
| June 2004 | - | $4.56 M(-62.3%) | $4.56 M(-70.9%) |
| Dec 2003 | $12.10 M(+24.6%) | - | - |
| June 2003 | - | $12.10 M(+239.0%) | $15.67 M(+45.3%) |
| Sept 2002 | - | $3.57 M(+4.3%) | $10.78 M(-1.6%) |
| June 2002 | - | $3.42 M(-9.7%) | $10.96 M(+3.9%) |
| Mar 2002 | - | $3.79 M(+1.3%) | $10.55 M(+5.8%) |
| Sept 2001 | - | $3.74 M(+24.3%) | $9.97 M(+10.4%) |
| June 2001 | - | $3.01 M(+12.0%) | $9.04 M(-0.8%) |
| Mar 2001 | - | $2.69 M(+411.4%) | $9.11 M(-6.3%) |
| Dec 2000 | $9.71 M(+83.3%) | $526.00 K(-81.3%) | $9.71 M(-0.8%) |
| Sept 2000 | - | $2.81 M(-9.0%) | $9.79 M(+9.0%) |
| June 2000 | - | $3.08 M(-6.5%) | $8.98 M(+19.8%) |
| Mar 2000 | - | $3.30 M(+449.7%) | $7.50 M(+41.4%) |
| Dec 1999 | $5.30 M(+341.7%) | $600.00 K(-70.0%) | $5.30 M(+12.8%) |
| Sept 1999 | - | $2.00 M(+25.0%) | $4.70 M(+74.0%) |
| June 1999 | - | $1.60 M(+44.9%) | $2.70 M(+144.9%) |
| Mar 1999 | - | $1.10 M | $1.10 M |
| Dec 1998 | $1.20 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual revenue?
- What is the all time high annual revenue for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual revenue year-on-year change?
- What is BioMarin Pharmaceutical quarterly revenue?
- What is the all time high quarterly revenue for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly revenue year-on-year change?
- What is BioMarin Pharmaceutical TTM revenue?
- What is the all time high TTM revenue for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM revenue year-on-year change?
What is BioMarin Pharmaceutical annual revenue?
The current annual revenue of BMRN is $2.42 B
What is the all time high annual revenue for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual revenue is $2.42 B
What is BioMarin Pharmaceutical annual revenue year-on-year change?
Over the past year, BMRN annual revenue has changed by +$323.19 M (+15.42%)
What is BioMarin Pharmaceutical quarterly revenue?
The current quarterly revenue of BMRN is $745.74 M
What is the all time high quarterly revenue for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly revenue is $745.74 M
What is BioMarin Pharmaceutical quarterly revenue year-on-year change?
Over the past year, BMRN quarterly revenue has changed by +$164.41 M (+28.28%)
What is BioMarin Pharmaceutical TTM revenue?
The current TTM revenue of BMRN is $2.75 B
What is the all time high TTM revenue for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM revenue is $2.75 B
What is BioMarin Pharmaceutical TTM revenue year-on-year change?
Over the past year, BMRN TTM revenue has changed by +$442.25 M (+19.14%)